Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 36548927

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2023 Apr 20
First author
Thieblemont C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2023 Mar;20(3):138. doi: 10.1038/s41571-023-00730-9.
    note
    Source null
    related pmid
    36646813
    relationship
    Comment in

Authors and identifiers

  1. name
    Thieblemont C
    type
    Author
  2. name
    Phillips T
    type
    Author
  3. name
    Ghesquieres H
    type
    Author
  4. name
    Cheah CY
    type
    Author
  5. name
    Clausen MR
    type
    Author
  6. name
    Cunningham D
    type
    Author
  7. name
    Do YR
    type
    Author
  8. name
    Feldman T
    type
    Author
  9. name
    Gasiorowski R
    type
    Author
  10. name
    Jurczak W
    type
    Author
  11. name
    Kim TM
    type
    Author
  12. name
    Lewis DJ
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Thieblemont C
    type
    Author
  2. name
    Phillips T
    type
    Author
  3. name
    Ghesquieres H
    type
    Author
  4. name
    Cheah CY
    type
    Author
  5. name
    Clausen MR
    type
    Author
  6. name
    Cunningham D
    type
    Author
  7. name
    Do YR
    type
    Author
  8. name
    Feldman T
    type
    Author
  9. name
    Gasiorowski R
    type
    Author
  10. name
    Jurczak W
    type
    Author
  11. name
    Kim TM
    type
    Author
  12. name
    Lewis DJ
    type
    Author
bibliography ids
  1. nci-bib-6d6485e587e410f9c4899f7c
book metadata
content sha256
1c2a3f7a3bcaf92219fbf74891b5c7f2570f487e647042d66dfde0fe4d3499e1
document type
citation
dois
  1. 10.1200/JCO.22.01725
electronic publication date
display
2022 Dec 22
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:36548927
immutable id
pubmed:36548927@1c2a3f7a3bcaf92219fbf74891b5c7f2570f487e647042d66dfde0fe4d3499e1
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
12
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
2238-2247
volume
41
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2023 Mar;20(3):138. doi: 10.1038/s41571-023-00730-9.
    note
    Source null
    related pmid
    36646813
    relationship
    Comment in
outcomes validated
false
pmid
36548927
provenance
batch id
d370e99271168e8a8a13
provider
NCBI PubMed ESummary
record sha256
790d8302dc1cf805c515583fa18c43504778c24af14c9dad8aab8cdfe1560b3f
response sha256
f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
retrieved at
2026-09-09T23:48:13.005737+00:00
publication date
display
2023 Apr 20
precision
day
year
2023
publication types
  1. Clinical Trial, Phase II
  2. Clinical Trial, Phase I
  3. Journal Article
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36548927/
title
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Preserved source evidence · Independent clinical review pending · Not medical advice